Endoglin (CD 105) as a potential prognostic factor in neuroblastoma

Area of Science:

• Oncology
• Cancer Biology
• Immunohistochemistry

Background:

• Endoglin (CD105) is a cytokine crucial for angiogenesis and is highly expressed in tumor vasculature.
• Intratumoral microvessel density (IMVD) assessed by CD105 is a prognostic indicator in various cancers.
• Neuroblastoma is a pediatric cancer where prognostic factors require further elucidation.

Purpose of the Study:

• To investigate the correlation between IMVD, assessed via CD105 staining, and the clinical outcome of pediatric neuroblastoma patients.
• To evaluate IMVD alongside other established prognostic factors in neuroblastoma.

Main Methods:

• Retrospective review of 38 neuroblastoma tumor specimens.
• Immunohistochemical analysis using CD105 antibodies to determine IMVD.
• Correlation of IMVD with prognostic factors (MYCN, stage, histopathology, age) and patient outcomes.

Main Results:

• IMVD was significantly higher in patients with unfavorable histology, metastatic disease, MYCN amplification, and high-risk group.
• Receiver Operating Characteristic (ROC) analysis identified a significant IMVD cut-off value for predicting event-free survival (EFS).
• Multivariate analysis confirmed MYCN amplification and IMVD as independent predictors of EFS.

Conclusions:

• Intratumoral microvessel density (IMVD) determined by CD105 staining is an independent prognostic factor for neuroblastoma.
• CD105-based IMVD assessment offers valuable prognostic information for pediatric neuroblastoma.